Siegfried Holding AG Stock London S.E.

Equities

0QQO

CH0014284498

Pharmaceuticals

Real-time Estimate Cboe Europe 06:06:10 2024-05-29 EDT 5-day change 1st Jan Change
880 CHF -0.23% Intraday chart for Siegfried Holding AG +0.23% +2.48%

Financials

Sales 2024 * 1.3B 1.43B 1.95B Sales 2025 * 1.42B 1.56B 2.13B Capitalization 3.77B 4.13B 5.64B
Net income 2024 * 148M 162M 221M Net income 2025 * 172M 188M 257M EV / Sales 2024 * 3.16 x
Net Debt 2024 * 351M 384M 525M Net Debt 2025 * 313M 343M 469M EV / Sales 2025 * 2.87 x
P/E ratio 2024 *
25.4 x
P/E ratio 2025 *
21.8 x
Employees 3,945
Yield 2024 *
0.44%
Yield 2025 *
0.46%
Free-Float 87.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.23%
1 week+0.23%
1 month+1.19%
3 months-0.95%
6 months+12.74%
Current year+2.48%
More quotes
1 week
879.00
Extreme 879
903.00
1 month
844.00
Extreme 844
903.00
Current year
828.00
Extreme 828
947.50
1 year
657.50
Extreme 657.5
947.50
3 years
566.50
Extreme 566.5
947.50
5 years
316.50
Extreme 316.5
947.50
10 years
137.49
Extreme 137.4855
947.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 17-04-30
Chief Tech/Sci/R&D Officer 56 19-03-31
Corporate Officer/Principal - 14-01-31
Members of the board TitleAgeSince
Director/Board Member 55 15-12-31
Director/Board Member 63 13-12-31
Chairman 61 09-12-31
More insiders
Date Price Change Volume
24-04-30 882 +26.36% 25
24-05-28 879 0.00% 218
24-05-27 879 -0.57% 122
24-05-24 884 -1.45% 18
24-05-23 897 +1.93% 285

Delayed Quote London S.E., April 30, 2024 at 11:40 am

More quotes
Siegfried Holding AG is a Switzerland-based life sciences company which is active in primary and secondary drug manufacturing. The Company produces both drug substances and drug products. The drug substance portfolio includes contract development and manufacturing of both active pharmaceutical ingredients (APIs) and intermediates. The drug products portfolio comprises licensing and contract or co-development and manufacturing of oral solids and sterile. The Company's products and substances are developed for treatment of hypertension, benign prostate hyperplasia, depression, chronic myeloid leukemia, glaucoma, asthma, schizophrenia and bipolar disorders and diabetes. The Company operates production facilities in Switzerland, Germany, France, Malta, the United States, China, and Spain.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
879 CHF
Average target price
1,016 CHF
Spread / Average Target
+15.57%
Consensus